Multiple Myeloma Data

Market Dynamics and Outcomes

Multiple myeloma affects approximately 35,000 people every year and has a survival rate just above 60%.  The market has become increasingly crowded for relapsed or refractory multiple myeloma with new approvals occurring for drugs that target BCMA and CD-38 (monoclonal antibodies and CAR-T therapy).  There is a very well-established clinical protocol for treatment of multiple myeloma which starts with immunomodulating agents such as Revlimid and Pomalyst, then moves to proteasome inhibitors (Velcade, Kyprolis, Ninlaro), and then to newer agents such as Darzalex and Sarclisa.  Therapeutic regimens (which typically involve combinations of the above), are among the most expensive in the oncology space and can approach $500,000 a year. However, core backbone products like Revlimid have recently gone generic. Seagrove Partners estimates the WW multiple myeloma drug market to be ~ $32 billion.